Evidence map›Paper›PMID 29143774›Full record

ArticleMolecules (Basel, Switzerland)2017

Disrupting VEGF-VEGFR1 Interaction: De Novo Designed Linear Helical Peptides to Mimic the VEGF

Beatriz Balsera, M Ángeles Bonache, Marie Reille-Seroussi, Nathalie Gagey-Eilstein, Michel Vidal, Rosario González-Muñiz, María Jesús Pérez de Vega

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Structure-Based Design of Peptides Targeting VEGF/VEGFRs.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Beatriz BalseraInstituto de Química-Médica (IQM-CSIC), Juan de la Cierva 3, Madrid 28006, Spain. bea.balsera@gmail.com.
M Ángeles BonacheInstituto de Química-Médica (IQM-CSIC), Juan de la Cierva 3, Madrid 28006, Spain. angelesbonache@iqm.csic.es.
Marie Reille-SeroussiUMR 8638 CNRS, UFR de Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, 4 avenue de l'Observatoire, Paris 75006, France. marie.reille@gmail.com.
Nathalie Gagey-EilsteinUMR 8638 CNRS, UFR de Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, 4 avenue de l'Observatoire, Paris 75006, France. nathalie.eilstein@parisdescartes.fr.
Michel VidalUMR 8638 CNRS, UFR de Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, 4 avenue de l'Observatoire, Paris 75006, France. michel.vidal@parisdescartes.fr.
Rosario González-MuñizInstituto de Química-Médica (IQM-CSIC), Juan de la Cierva 3, Madrid 28006, Spain. iqmg313@iqm.csic.es.
María Jesús Pérez de VegaInstituto de Química-Médica (IQM-CSIC), Juan de la Cierva 3, Madrid 28006, Spain. pdevega@iqm.csic.es.ORCID 0000-0001-5095-5882
Instituto de Química Médica · ESDélégation Paris 5 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interaction between vascular endothelial growth factor (VEGF) and its receptors (VEGFR) has important implications in angiogenesis and cancer, which moved us to search for peptide derivatives able to block this protein-protein interaction. In a previous work we had described a collection of linear 13-mer peptides specially designed to adopt helical conformations (Ac-SSEE

Indexed as

Amino Acid SequenceBinding SitesHumansPeptide LibraryPeptidesProtein BindingProtein Structure, SecondaryVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Peptide LibraryPeptidesVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1VEGFA protein, humanangiogenesispeptidesprotein–protein interactionsVEGF-VEGFR1α-helix

Identifiers

PMID29143774
PMCPMC6150346
OpenAlexW2765628276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.